NBD AI Bulletin - Hangzhou Tigermed Consulting Co., Ltd. (the Company, SZ 300347, close price: 125.3 yuan) announced on March 8 that Cao Xiaochun, who holds a stake of more than 5% in the Company, on March 4, 2021 pledged 750,000 shares, accounting for 1.31% of her holdings. As of the date of this notice, the total number of pledged shares of Cao Xiaochun stood at 750,000 shares, accounting for 1.31% of her holdings.

According to the Company's 2020 semi-annual report, Hangzhou Tigermed Consulting Co., Ltd. mainly engages in services, accounting for 99.52% of its revenue.

Hangzhou Tigermed Consulting Co., Ltd. is chaired by Ye Xiaoping, male, 58, Chinese national, no permanent residence abroad, Ph.D. from University of Oxford, the UK. The Company's general manager is Cao Xiaochun, 52, Chinese national, no permanent residence abroad, bachelor's degree, practicing pharmacist, deputy senior engineer.

Tips on "Stock Trends":

1. The number of shares held by northbound investors in the Company decreased by 8.8478 million over the past 30 days, representing 2.51% of the Company's circulating shares;

2. There was no institutional research on the Company in the past 30 days.

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.